Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

2.500 USD +0.030 (+1.21%)
Official Closing Price Updated: 5:17 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 460,472
Open 2.440
Bid (Size) 2.460 (1)
Ask (Size) 2.490 (2)
Prev. Close 2.470
Today's Range 2.430 - 2.584
52wk Range 2.370 - 5.190
Shares Outstanding 51,493,571
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism... 
From Business Wire News Releases
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell... 
From Business Wire News Releases

Performance

YTD
-32.98%
-32.98%
1 Month
-27.75%
-27.75%
3 Month
-34.04%
-34.04%
6 Month
-23.78%
-23.78%
1 Year
-2.34%
-2.34%

More News

Read More
GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting
From Business Wire News Releases
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
From Business Wire News Releases
5 Penny Stock To Watch In March 2021 With Potential Biotech Catalysts
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
From Business Wire News Releases
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
From ACN Newswire
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
From GlobeNewswire News Releases
GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
From Business Wire News Releases
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
From Business Wire News Releases
GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.